A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect
IET Nanobiotechnology · 2023
DOI: 10.1049/nbt2.12119 ↗Kurz gefasst
Fachartikel in der Zeitschrift IET Nanobiotechnology, 2023. Verfasst von Changhai Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
As a first‐line anticancer drug, paclitaxel has shortcomings, such as poor solubility and lack of tumour cell selectivity, which limit its further applications in clinical practice. Therefore, the authors aimed to utilise the characteristics of prodrug and nanotechnology to prepare a reactive oxygen species (ROS) and GSH dual‐responsive targeted tumour prodrug nanoparticle Man‐PEG‐SS‐PLGA/ProPTX to improve the clinical application status of paclitaxel limitation. The characterisation of Man‐PEG‐SS‐PLGA/ProPTX was carried out through preparation. The cytotoxicity of nanoparticles on tumour cells and the effect on apoptosis of tumour cells were investigated by cytotoxicity assay and flow cytometry analysis. The ROS responsiveness of nanoparticles was investigated by detecting the ROS level of tumour cells. The tumour cell selectivity of the nanoparticles was further investigated by receptor affinity assay and cell uptake assay. The particle size of Man‐PEG‐SS‐PLGA/ProPTX was (132.90 ± 1.81) nm, the dispersion coefficient Polymer dispersity index was 0.13 ± 0.03, and the Zeta potential was (−8.65 ± 0.50) mV. The encapsulation rate was 95.46 ± 2.31% and the drug load was 13.65 ± 2.31%. The nanoparticles could significantly inhibit the proliferation and promote apoptosis of MCF‐7, HepG2, and MDA‐MB‐231 tumour cells. It has good ROS response characteristics and targeting. The targeted uptake mechanism is energy‐dependent and endocytosis is mediated by non‐clathrin, non‐caveolin, lipid raft/caveolin, and cyclooxygenase (COX)/caveolin with a certain concentration dependence and time dependence. Man‐PEG‐SS‐PLGA/ProPTX is a tumour microenvironment‐responsive nanoparticle that can actively target tumour cells. It restricts the release of PTX in normal tissues, enhances its selectivity to tumour cells, and has significant antitumour activity, which is expected to solve the current limitations of PTX use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Beijing University of Chinese Medicine, Beijing, China.
- Thammasat University, Pathum Thani, Thailand.
ORCID-Profile: Yang Lu, Jinling Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, C., Jiao, Y., Zhang, X., Guo, M., Zhang, Q., Hu, W., Dong, S., Jakkree, T., Lu, Y., & Wang, J. (2023). A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect. IET Nanobiotechnology. https://doi.org/10.1049/nbt2.12119
Vancouver
Wang C, Jiao Y, Zhang X, Guo M, Zhang Q, Hu W, et al. A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect. IET Nanobiotechnology. 2023. doi:10.1049/nbt2.12119
BibTeX
@article{Wang2023,
author = {Wang, Changhai and Jiao, Yuwen and Zhang, Xinyu and Guo, Mingxue and Zhang, Qing and Hu, Wenjun and Dong, Shuang and Jakkree, Tangthianchaichana and Lu, Yang and Wang, Jinling},
title = {A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect},
journal = {IET Nanobiotechnology},
year = {2023},
doi = {10.1049/nbt2.12119}
}
EUVIMED